Summary of Seer Conference Call (November 20, 2025) Company Overview - **Company**: Seer (NasdaqGS:SEER) - **Industry**: MedTech Diagnostics and Proteomics - **Product**: Proteograph Product Suite, including Proteograph One and SP200 Key Points and Arguments Product Development and Performance - Seer launched the Proteograph Product Suite to enable deep, unbiased proteomic analysis at scale, significantly improving throughput and reducing costs compared to earlier iterations [3][4] - The latest product, Proteograph One, was launched in June 2025, allowing customers to conduct larger studies with reduced assay time and increased sample throughput [4][5] - Notable studies include a 20,000-sample study by Korea University and a $50 million NIH-funded multi-center grant for a 50,000-sample study, where Seer was selected as the sole proteomic platform [5][6][7] Customer Validation and Publication Velocity - Since the launch of the first product in 2021, 66 customer papers have been published, with 13 published in Q3 2023 alone, indicating increasing customer validation and biological insights [7][8] - The establishment of Prognomic, a spin-out focused on liquid biopsy, has led to the development of a best-in-class lung cancer test, showcasing the effectiveness of Seer's platform [8][9] Market Adoption and Customer Feedback - Customer feedback on the Proteograph One has been positive, with a significant increase in instrument placements from 11 in the previous year to nearly 30 in the first nine months of 2025 [10][11] - The platform is being adopted for various applications, including neurodegenerative diseases and biomanufacturing, demonstrating its versatility [11][12] Strategic Partnerships - Seer has formed a partnership with Thermo, enhancing their market presence through co-sales, which allows Thermo sales representatives to offer Seer's Proteograph alongside their mass spectrometry instruments [25][26] - The combination of Seer's technology with Thermo's instruments provides a significant increase in the depth of proteomic analysis, achieving 8-10 times more protein identification compared to Thermo's instruments alone [26][27] Commercial Strategy and Customer Engagement - Seer's stack and Strategic Instrument Placement (SIP) programs have been effective in driving platform adoption, with a significant portion of instrument placements coming from former stack customers [30][33] - The SIP program allows customers to borrow instruments, facilitating adoption in budget-constrained academic and government settings [32][33] Financial Outlook and Capital Allocation - Seer ended Q3 2025 with approximately $251 million in cash and reaffirmed a break-even runway, focusing on diligent capital management while investing in innovation [35][37] - The company aims to reach a revenue scale of around $100 million, leveraging its strong balance sheet to potentially acquire less capital-intensive technologies [39][40] Future Developments - Seer anticipates an increase in population-scale studies, predicting that 2026 will see the first 100,000-sample study conducted using mass spectrometry [41][42] - The company is focused on generating biological insights from these studies to drive revenue growth [42] Additional Important Insights - The scientific community's skepticism towards new platforms is acknowledged, emphasizing the importance of evidence and robust performance in gaining institutional confidence [13][14] - The complexity of proteomics is highlighted, with a call for deeper analysis at the peptide level to uncover significant biological variations that could inform health and disease understanding [19][20][24]

Q3'26 Quarterly Results November 20, 2025 This presentation and associated commentary contain forward-looking statements regarding Veeva's expected future performance and, in particular, includes guidance, provided as of November 20, 2025, about Veeva's expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that ac ...

Q3 Fiscal 2025 THIRD QUARTER RESULTS November 20, 2025 FORWARD LOOKING STATEMENTS These materials and related earnings press release and conference call contain forward -looking statements within the "safe harbo r" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than those that are purely historical are forward -looking statements. Forwar d-looking statements include statements identified as such in our November 20, 2025, earnings press release. Because these forward ...

ESCO Technologies Fourth Quarter FY 2025 Earnings Call Bryan Sayler President & CEO Chris Tucker Sr. Vice President & CFO November 20, 2025 2 Q4 Results – Continuing Operations ($ in Millions, except per share amounts) 273.5 Q4'24 Q4'25 Sales 247.5 320.9 Q4'24 Q4'25 Entered Orders 62.6 84.4 Q4'24 Q4'25 Adjusted EBIT 23.9% 22.9% $1.79 1 Forward Looking Statement Statements in this presentation regarding Management's intentions, expectations and guidance for fiscal 2026, including restructuring and cost reduc ...

Corporate Overview and Q2FY26 Financial Results November 20, 2025 Forward Looking Statements; Use of Non-GAAP Measures This presentation and the accompanying oral presentation contain forward-looking statements that involve substantial risks and uncertainties, which include, but are not limited to, statements regarding our expected financial results for the fiscal quarter ending January 31, 2026 and fiscal year ending April 30, 2026, our strategic areas of focus, expectations and plans regarding our future ...

Acacia Research FY Conference Summary Company Overview - **Company Name**: Acacia Research (Ticker: ACTG) - **Market Cap**: $313 million - **Book Value**: Approximately $577 million - **Common Shares Outstanding**: 96 million - **Business Model**: Focuses on acquiring under-managed and under-loved businesses, particularly in the B and C quartile asset categories [3][4] Core Business Strategy - **Investment Focus**: Acacia Research aims to buy businesses at a price that provides a significant margin of safety, allowing for potential operational improvements and value creation [4][5] - **Operational Improvements**: The company emphasizes operational enhancements post-acquisition, aiming to generate free cash flow and earnings growth [4][10] - **Acquisition Strategy**: The company has shifted from being a patent troll to a value investor, focusing on small-cap and micro-cap companies [5][21] Recent Acquisitions - **Benchmark Energy**: Acquired a 51% stake in 2023, followed by a larger acquisition in 2024. The acquisition was made during a period when oil and gas prices were low, allowing for a favorable purchase price [6][7] - **Deflecto**: Acquired over a year ago at approximately 5.5 times mid-cycle EBITDA. The business has faced tariff-related demand issues but is expected to perform well post-cycle [10][11] - **Printroducts**: Undergoing a turnaround with operational improvements [14] Financial Performance - **EBITDA Growth**: The company has seen EBITDA growth that exceeds parent costs, indicating operational efficiency [17] - **Cash Returns**: Benchmark is generating high teens cash returns, while Deflecto and Printroducts are also yielding significant cash returns [15][24] - **Cash Management**: The company has maintained a stable cash position, starting with $350 million and ending with approximately $330 million after acquisitions and buybacks [13][14] Market Position and Competitive Advantage - **Talent Acquisition**: Acacia Research leverages a network of operating partners to enhance operational performance in acquired businesses, which individual businesses may struggle to attract [26][27] - **Focus on Microcap Opportunities**: The company identifies value traps in small and micro-cap companies that larger funds may overlook [22][23] Risk Management and Future Outlook - **Leverage Strategy**: The company maintains a conservative approach to leverage, focusing on unlevered and levered cash flow returns [24] - **Long-term Vision**: Acacia Research aims for a turnaround period of 12 to 18 months for its acquisitions to show significant results [20] - **Market Engagement**: The company plans to increase its visibility in the investment community as it continues to demonstrate operational improvements and financial performance [20] Additional Insights - **Partnership with Unchain**: Engaged in a partnership to underwrite commercial loans secured by Bitcoin, providing a cash management option with attractive returns [12][13] - **Cost Structure Management**: The company has rationalized its corporate cost structure to enhance profitability [17] This summary encapsulates the key points from the Acacia Research FY Conference, highlighting the company's strategic focus, recent acquisitions, financial performance, and future outlook.

Summary of Distribution Solutions Group (DSGR) FY Conference Call Company Overview - **Company**: Distribution Solutions Group (NasdaqGS: DSGR) - **Formation**: Formed in early 2022 by merging three specialty distributors serving different end markets [2][3] - **Revenue**: Approximately $2 billion with an EBITDA of about $190 million, up from less than $1 billion in revenue and $90 million in EBITDA in 2021 [3] Business Verticals 1. **Lawson Products**: - Focuses on MRO (Maintenance, Repair, and Operations) with about 930 sales reps serving 80,000 customers [4][11] - Average piece price is around $1.20, emphasizing high volume and low-cost items critical for customer operations [5] - Provides vendor-managed inventory (VMI) services, integrating deeply into customer operations [4][5] 2. **Gexpro Services**: - OEM-focused, dealing with Class C parts like rivets and screws, serving about 2,500 customers [6][11] - Represents 5-6% of overall production costs but constitutes 50-60% of unit volume [6] - High customer retention rates of approximately 98% [25] 3. **TestEquity Group**: - Accounts for about 40% of overall sales, primarily in test and measurement equipment [8][11] - Focus on improving e-commerce and inside sales to increase customer engagement [27] Growth Strategy - **M&A Activities**: M&A is a significant part of the growth strategy, with nine acquisitions made since the formation of DSGR, deploying about $550 million in capital [28] - **Organic Growth**: Achieved a 6% organic sales increase in Q3, with consistent growth over the last four quarters despite a sluggish industrial backdrop [15][31] - **Capital Allocation**: Maintains a leverage ratio of about 3.5 times, with a focus on working capital efficiency and share repurchase programs [29][30] Financial Performance - **Q3 Results**: Reported solid top-line growth, with EBITDA dollars relatively flat sequentially [31] - **Historical Growth**: EBITDA increased from $90 million to a run rate of $190 million in three years [31] Market Position and Challenges - **Market Diversification**: DSGR serves a wide range of end markets, minimizing concentration risk [20][11] - **Stock Performance**: Despite operational improvements, stock price has not reflected the company's performance, attributed to market misunderstandings and liquidity issues [34][35] Future Outlook - **Focus Areas**: Excitement around the TestEquity Group's new leadership and roadmap for growth, aiming to improve margins above 10% [36] - **Investment in People**: Strategic investments in personnel and sales teams to enhance revenue opportunities [26][27] Key Takeaways - DSGR is positioned as a specialty distributor with a strong focus on customer service and operational efficiency - The company has successfully integrated its three verticals, leveraging synergies for growth - Future growth is expected through continued M&A, organic growth strategies, and improvements in operational performance across its business segments [12][36]

Franklin Covey FY Conference Summary Company Overview - **Company Name**: Franklin Covey (NYSE: FC) - **Business Model**: Transitioned from paper planners to a subscription-based model focused on leadership development and organizational performance improvement [1][2][3] Core Business Areas 1. **Leadership Development**: Partnering with organizations to enhance leadership skills at all levels [3][4] 2. **Interpersonal Effectiveness**: Improving team communication, collaboration, and accountability [3] 3. **Culture and Trust**: Enhancing organizational culture and trust levels [3] 4. **Strategy Execution**: Assisting organizations in aligning and executing their strategies [4] Financial Performance - **Revenue**: Reported $267 million in revenue, with $225 million from subscriptions and services [5][6] - **Gross Margin**: Approximately 82-83% overall, with near 100% margin on subscription revenue and about 65% on services [6] - **Adjusted EBITDA**: $29 million, down from $56 million the previous year [19] - **Free Cash Flow**: Generated about $250 million over the last 10 years, with 80-83% used for share buybacks [21] Strategic Changes - **Sales Transformation**: Invested $16 million to restructure the salesforce into dedicated hunters and farmers to improve account management and new client acquisition [17][19] - **Market Challenges**: Faced revenue decline due to external factors like DOGE and internal transitions, leading to a flattening of subscription growth [18][19] - **Future Expectations**: Anticipated growth in invoiced amounts and deferred revenue, expecting a return to higher revenue growth rates in fiscal 2027 [20][27] Subscription Model - **All Access Pass**: Subscription model sold on a per-head basis, with a one-year minimum commitment [4] - **Service Attach Rate**: For every dollar of subscription revenue, approximately $0.50 comes from professional services [5][40] - **Retention Rates**: Education division has an 85% retention rate, while enterprise client retention historically above 90% [50][51] Investment in Content and Technology - **Annual Investment**: Approximately 9-10% of prior year's revenue invested in content and technology development [4][44] - **New Solutions**: Recently launched solutions focused on AI leadership and cultural adaptation to AI [46][48] Market Position and Client Base - **Client Examples**: Notable clients include Marriott, which utilizes Franklin Covey's subscription for improving guest satisfaction [9][10] - **Education Market**: The Leader in Me program is used in about 8,000 schools, focusing on personal leadership skills for students [11][12] Conclusion - **Outlook**: The company is optimistic about future growth driven by recent strategic changes and investments in content and technology, with expectations for improved financial performance in the coming years [20][27]

Financial Performance Summary - Total Revenue for FY'25 reached $18831 million, a 16% increase year-over-year[2] - The company projects total revenue for FY'26 to be between $20997 million and $21186 million, representing a 12%-13% year-over-year growth[2] - Non-GAAP Diluted EPS for FY'25 was $2015, and the guidance for FY'26 is $2298-$2318[2] - GAAP Operating Income for FY'25 was $4923 million, compared to $3630 million in FY'24[2] Segment Performance - Global Business Solutions revenue for FY'25 was $11077 million, a 16% increase year-over-year[2] - TurboTax revenue for FY'25 was $4933 million, a 9% increase year-over-year[2] - Credit Karma revenue for FY'25 was $2200 million, a 34% increase year-over-year[2] - Consumer segment revenue for FY'25 reached $7754 million, a 15% increase year-over-year[2] Platform Revenue - Combined Platform Revenue increased from $12520 million in FY'24 to $14902 million in FY'25[3]

Quantum-Si Conference Call Summary Company Overview - **Company**: Quantum-Si (NasdaqGM:QSI) - **Industry**: Life Sciences Tools and Diagnostics - **Technology**: Utilizes semiconductor chip technology for single-molecule protein sequencing with products including the Platinum instrument and QSI Cloud software [3][4] Key Points and Arguments Product Portfolio and Technology - **Current Products**: The first-generation technology includes the Platinum and Platinum Pro instruments, which have been in the market for about three years [4] - **Business Model**: Operates on a razor-razor blade model where customers purchase the machine and consumables for sample preparation and sequencing [4] - **Upcoming Product**: The Proteus platform represents a significant architectural change, moving optics from consumables to the machine, allowing for higher sequencing output and lower-cost consumables [5][15] Financial Performance and Strategy - **Recent Earnings**: The company has adapted to NIH headwinds by offering alternative purchasing options for the Platinum machine, resulting in 12 machines sold under this program, with over half going to academia [6] - **Publications**: Five publications have been released this year, indicating a strong pipeline and market development [6] - **Cash Position**: Ended Q3 2025 with over $230 million in cash, providing a runway into Q2 2028, which includes 18 months post-Proteus launch [44][46] Proteus Development and Launch Timeline - **Milestones**: Completed sequencing on over 50 runs of the Proteus prototype, achieving this milestone ahead of schedule [7][8] - **Launch Timeline**: Expected to launch Proteus by the end of 2026 [21][22] - **Early Access Program**: Targeting big centers with core labs for testing and comparison against existing technologies [26][28] Pricing Strategy - **Price Range**: Anticipated pricing for Proteus is between $300,000 and $500,000, reflecting its advanced capabilities compared to the current Platinum device priced at $125,000 [23][24] - **Market Accessibility**: The pricing strategy aims to balance value capture with accessibility to avoid constraining the number of potential users [25] R&D and Technological Advancements - **AI and Binding Kinetics**: The integration of AI tools has accelerated the development of engineered protein recognizers, enhancing the ability to achieve full proteome coverage [30][31] - **Proteome Coverage Goals**: Aiming to demonstrate coverage of all 20 amino acids by 2026, which would enable advanced applications in single amino acid variants and post-translational modifications (PTMs) [33] Commercialization Strategy - **Sales Strategy**: Considering various sales models for Proteus, including trade-ins for existing Platinum users, while leaning towards capital sales [39][40] - **Long-term Focus**: Emphasis on capital efficiency and targeted investments to support the Proteus launch and subsequent commercialization efforts [46][47] Additional Important Insights - **Engineering and Chemistry Hurdles**: Early data from Proteus shows improvements across all metrics compared to the Platinum machine, indicating a de-risked program moving towards commercialization [10][12] - **Controlled Cleavage Technology**: Future versions of Proteus may incorporate controlled cleavage technology to enhance sequencing capabilities [41][43] - **Strategic Opportunities**: Open to exploring strategic opportunities and technologies that align with Quantum-Si's goals, while maintaining focus on the Proteus launch [47]